← Human Trials & Peer-Reviewed Studies
Astaxanthin supplement improves clinical outcomes, quality of life, and inflammatory factors in patients with rheumatoid arthritis: a randomized clinical trial.
Plain-language guide to PMID 40569081 (2025): randomized controlled trial of Copper (Supplement) in 60 patients, rheumatoid arthritis.
Key Facts
- PMID
- 40569081
- Journal
- Food & function
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Grigorian A et al. (6 authors)
- DOI
- 10.1039/d5fo00949a
What This Study Did, in Plain Language
What Was Tested
Researchers studied Copper (Supplement) in the context of rheumatoid arthritis in this randomized controlled trial publication.
This study aimed to determine the effect of astaxanthin (ASX) on clinical outcomes, quality of life, and inflammatory factors in patients with RA.
Why It Was Studied
Rheumatoid Arthritis (RA) is a chronic, systemic inflammatory disease that results in joint destruction and progressive disability.
Fasting blood samples were obtained from patients at the beginning and end of the intervention to measure the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and interleukin-6 (IL-6).
Who Took Part
The abstract describes 60 patients taking part.
By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized and placebo-controlled study.
Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
A placebo (an inactive look-alike) gave the Copper (Supplement) group a baseline to be compared against.
What Was Measured
Fasting blood samples were obtained from patients at the beginning and end of the intervention to measure the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and interleukin-6 (IL-6).
Clinical symptoms were also measured, including the pain intensity based on the visual analogue scale (VAS), Disease Activity Score 28 (DAS-28), and Health Assessment Questionnaire (HAQ).
PubMed files the paper under topics including Quality of Life, Arthritis, Rheumatoid, Xanthophylls, Dietary Supplements, C-Reactive Protein, Interleukin-6 and Blood Sedimentation.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Copper (Supplement) in 60 patients in people with rheumatoid arthritis.
The publication is from 2025 (Food & function), a journal based in England.
More context: the Copper (Supplement) compound page, Rheumatoid arthritis research.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.